Unlock The Potential Of GPEx® Lightning: Accelerate Your HEK Cell Line Development

By Jessica Anderson, Ph.D. Principal Scientist, Research and Development, Catalent Biologics

When your biologics program depends on human glycosylation patterns or precise post-translational modifications, CHO cells simply won't cut it. Yet traditional HEK cell line development has long meant accepting timelines of seven to eight months before you even reach cell bank creation. That bottleneck costs time, capital, and competitive ground.

A new approach to HEK cell line engineering is changing that calculus. By applying the same precision integration technology proven across more than 90 clinical and 20 commercial biologics to a human embryonic kidney platform, it is now possible to generate candidate cell banks in approximately four months, a reduction of nearly 50%. Average titers improve by 30%, and an optimized optofluidic cloning workflow achieves greater than 70% single-cell cloning efficiency, producing clones with titers more than four times higher than their originating pools.

For developers working on viral vectors, multispecifics, Fc-fusion proteins, or other complex recombinant proteins, this means earlier access to material for assay development and animal studies, more predictable scale-up from bench to GMP bioreactors, and the ability to predefine gene expression ratios at transfection to eliminate downstream promoter optimization.

You will also learn how stoichiometric control over multi-gene constructs simplifies process design and maintains consistent product quality from the outset. Download the full executive summary now to see how these advances translate into faster, more reliable paths from molecule to market.